Printer Friendly

Addendum to "Treatment of rheumatoid arthritis with biological agents--as a typical and common immune-mediated inflammatory disease" [Proc. Jpn. Acad., Ser. B 93, No. 8, 600-608].

Table 1 was updated, because Sarilumab, anti-IL-6 receptor mAb has been approved for RA in Japan.

doi: 10.2183/pjab.94.005

By Tsutomu TAKEUCHI
Table 1. Target molecules in immune-mediated inflammatory diseases

target                        biologies      RA      JIA       CD
                                            joint   joint   intestine

TNF[alpha]       Ligand      adalimumab      (a)     (a)       (a)
                            certoiizumab     (a)     (b)       (a)
                                pegoi
                              goiimumab      (a)     (b)
                             infliximab      (a)     (d)       (a)
                 Receptor    etanercept      (a)     (a)
                              sirukumab      (b)
                 Ligand     clazakizumab     (b)               (d)
IL-6                         olokizumab      (b)               (d)
                            vobarilizumab    (b)
                 Receptor    tocilizumab     (a)     (a)       (d)
                              sarilumab      (a)
GM-CSF           Ligand       namilumab     trial
                 Receptor   mavrilimumab     (b)
IL-1[beta]       Ligand      canakinumab     (d)     (a)
                             rilonacept      (c)     (c)
                 Receptor     anakinra       (a)     (a)
IL-12/23 (p40)               ustekinumab     (c)               (a)
                             guselkumab      (c)
IL-23 (p19)                 risankizumab                       (b)
                            tildrakizumab
                             brazikumab                        (c)
                 Ligand      ixekizumab      (c)
IL-17                        secukinumab     (c)               (d)
                 Receptor    brodalumab      (d)               (d)
BAFF                          belimumab      (c)
                             blisibimod
IFN[alpha]       Ligand      sifalimumab
                 Receptor    anifrolumab
CD80/86                       abatacept      (a)     (a)       (c)
CD20                          rituximab      (a)
Integrin [alpha]4/[beta]1    natalizumab     (d)               (a)
Integrin [alpha]4/[beta]7    vedolizumab                       (a)
                             etrolizumab                       (b)

target                        biologies        UC        AS      SpA
                                            intestine   spine   spine

TNF[alpha]       Ligand      adalimumab        (a)       (a)
                            certoiizumab      trial      (a)     (a)
                                pegoi
                              goiimumab        (a)       (a)
                             infliximab        (a)       (a)
                 Receptor    etanercept                  (a)     (b)
                              sirukumab
                 Ligand     clazakizumab
IL-6                         olokizumab
                            vobarilizumab
                 Receptor    tocilizumab                 (d)
                              sarilumab                  (d)
GM-CSF           Ligand       namilumab
                 Receptor   mavrilimumab
IL-1[beta]       Ligand      canakinumab
                             rilonacept
                 Receptor     anakinra
IL-12/23 (p40)               ustekinumab       (b)               (b)
                             guselkumab
IL-23 (p19)                 risankizumab                 (c)
                            tildrakizumab
                             brazikumab
                 Ligand      ixekizumab                  (b)     (b)
IL-17                        secukinumab                 (a)     (b)
                 Receptor    brodalumab                          (b)
BAFF                          belimumab
                             blisibimod
IFN[alpha]       Ligand      sifalimumab
                 Receptor    anifrolumab
CD80/86                       abatacept        (c)       (d)
CD20                          rituximab                  (c)
Integrin [alpha]4/[beta]1    natalizumab       (c)
Integrin [alpha]4/[beta]7    vedolizumab       (a)
                             etrolizumab       (b)

target                        biologies      PS      PsA    CAPS
                                            skin    skin&    FMF
                                                    joint   fever

TNF[alpha]       Ligand      adalimumab      (a)     (a)
                            certoiizumab     (b)     (a)
                                pegoi
                              goiimumab              (a)
                             infliximab      (a)     (a)
                 Receptor    etanercept      (a)     (a)
                              sirukumab
                 Ligand     clazakizumab             (c)
IL-6                         olokizumab
                            vobarilizumab
                 Receptor    tocilizumab
                              sarilumab
GM-CSF           Ligand       namilumab      (c)
                 Receptor   mavrilimumab
IL-1[beta]       Ligand      canakinumab                     (a)
                             rilonacept                      (a)
                 Receptor     anakinra      trial            (a)
IL-12/23 (p40)               ustekinumab     (a)     (a)
                             guselkumab      (b)     (c)
IL-23 (p19)                 risankizumab     (b)     (b)
                            tildrakizumab    (b)
                             brazikumab
                 Ligand      ixekizumab      (a)     (a)
IL-17                        secukinumab     (a)     (a)
                 Receptor    brodalumab      (a)     (a)
BAFF                          belimumab
                             blisibimod
IFN[alpha]       Ligand      sifalimumab
                 Receptor    anifrolumab
CD80/86                       abatacept     trial    (a)
CD20                          rituximab
Integrin [alpha]4/[beta]1    natalizumab
Integrin [alpha]4/[beta]7    vedolizumab
                             etrolizumab

target                        biologies       SLE       pSS      BD
                                            systemic   eye&    mucosa
                                                       mouth

TNF[alpha]       Ligand      adalimumab                         (a)
                            certoiizumab
                                pegoi
                              goiimumab
                             infliximab       (c)               (a)
                 Receptor    etanercept
                              sirukumab
                 Ligand     clazakizumab
IL-6                         olokizumab
                            vobarilizumab    trial
                 Receptor    tocilizumab       x
                              sarilumab
GM-CSF           Ligand       namilumab
                 Receptor   mavrilimumab
IL-1[beta]       Ligand      canakinumab
                             rilonacept
                 Receptor     anakinra
IL-12/23 (p40)               ustekinumab     trial
                             guselkumab
IL-23 (p19)                 risankizumab
                            tildrakizumab
                             brazikumab
                 Ligand      ixekizumab
IL-17                        secukinumab
                 Receptor    brodalumab
BAFF                          belimumab       (a)       (c)
                             blisibimod       (d)
IFN[alpha]       Ligand      sifalimumab      (c)
                 Receptor    anifrolumab      (b)
CD80/86                       abatacept       (d)      trial
CD20                          rituximab       (c)       (c)
Integrin [alpha]4/[beta]1    natalizumab
Integrin [alpha]4/[beta]7    vedolizumab
                             etrolizumab

target                        biologies     SSc     GCA       TA
                                            skin   large    large
                                                   vessel   vessel

TNF[alpha]       Ligand      adalimumab
                            certoiizumab
                                pegoi
                              goiimumab
                             infliximab
                 Receptor    etanercept
                              sirukumab
                 Ligand     clazakizumab
IL-6                         olokizumab
                            vobarilizumab
                 Receptor    tocilizumab    (c)     (a)      (b)
                              sarilumab
GM-CSF           Ligand       namilumab
                 Receptor   mavrilimumab
IL-1[beta]       Ligand      canakinumab
                             rilonacept
                 Receptor     anakinra
IL-12/23 (p40)               ustekinumab
                             guselkumab
IL-23 (p19)                 risankizumab
                            tildrakizumab
                             brazikumab
                 Ligand      ixekizumab
IL-17                        secukinumab
                 Receptor    brodalumab
BAFF                          belimumab
                             blisibimod
IFN[alpha]       Ligand      sifalimumab
                 Receptor    anifrolumab
CD80/86                       abatacept
CD20                          rituximab
Integrin [alpha]4/[beta]1    natalizumab
Integrin [alpha]4/[beta]7    vedolizumab
                             etrolizumab

target                        biologies      AAV      AOSD
                                            small    fever&
                                            vessel   joint

TNF[alpha]       Ligand      adalimumab
                            certoiizumab
                                pegoi
                              goiimumab
                             infliximab
                 Receptor    etanercept
                              sirukumab
                 Ligand     clazakizumab
IL-6                         olokizumab
                            vobarilizumab
                 Receptor    tocilizumab             trial
                              sarilumab
GM-CSF           Ligand       namilumab
                 Receptor   mavrilimumab
IL-1[beta]       Ligand      canakinumab              (a)
                             rilonacept
                 Receptor     anakinra
IL-12/23 (p40)               ustekinumab
                             guselkumab
IL-23 (p19)                 risankizumab
                            tildrakizumab
                             brazikumab
                 Ligand      ixekizumab
IL-17                        secukinumab
                 Receptor    brodalumab
BAFF                          belimumab      (b)
                             blisibimod
IFN[alpha]       Ligand      sifalimumab
                 Receptor    anifrolumab
CD80/86                       abatacept
CD20                          rituximab      (a)
Integrin [alpha]4/[beta]1    natalizumab
Integrin [alpha]4/[beta]7    vedolizumab
                             etrolizumab

(a) approved, primarily in Japan, except for anakinra and rituximab
for RA and abatacept for PsA (September 11, 2017). (b) positive
results in Phase 2 or 3 trial, (c) proof of concept obtained, (d) no
positive results in Phase 2 or 3,

RA: rheumatoid arthritis, JIA: juvenile idiopathic arthritis, CD:
Crohn's disease, UC: ulcerative colitis, AS: ankylosing spondylitis,
SpA: spondyloathritis, PS: psoriasis, PsA: psoriatic arthritis, CAPS:
cryopyrin associated periodic syndrome, FMF: familial medetrian
fever, SLE: systemic lupus erythematosus, pSS: primary Sjogren's
syndrome, SSc: systemic sclerosis, CCA: giant cell arthritis, TA:
Takayasu arteritis, AAV: ANCA associated vasculitis, AOSD:
adult-onset Still's disease
COPYRIGHT 2018 The Japan Academy
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Takeuchi, Tsutomu
Publication:Japan Academy Proceedings Series B: Physical and Biological Sciences
Article Type:Disease/Disorder overview
Date:Jan 1, 2018
Words:759
Previous Article:Chemical characteristics of hadal waters in the Izu-Ogasawara Trench of the western Pacific Ocean.
Next Article:Exploring peptide hormones in plants: identification of four peptide hormone-receptor pairs and two post-translational modification enzymes.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters